NASDAQ$APLT
Applied Therapeutics Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2021.
Applied Therapeutics reported its Q1 2021 financial results, highlighting the progression of late-stage programs towards commercialization in Galactosemia and Diabetic Cardiomyopathy, and advancement of rare disease programs in SORD and PMM2-CDG. The company ended the quarter with $148.1 million in cash and cash equivalents and short-term investments.
- Phase 2 pilot study of AT-007 initiated in patients with SORD Deficiency.
- NDA submission for AT-007 in Galactosemia expected no later than Q3 2021; commercial preparations ongoing.
- Completion of enrollment in ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy on track for mid-2021.
- Ended 1Q21 with a strong balance sheet of $148.1 million in cash and cash equivalents and short-term investments.
Headline financials
Revenue & EPS history
Applied Therapeutics · Revenue · Quarterly
$1M
Forward guidance
The press release contains forward-looking statements regarding the timing of NDA submission for AT-007, rare disease franchise expansion programs, clinical trials, and regulatory approval of product candidates.
Tailwinds
- Timing of NDA submission for potential approval of AT-007, which will include data from the ACTION-Galactosemia Kids trial and the 90-day safety data in adults with Galactosemia
- Timing of rare disease franchise expansion programs in SORD Deficiency and PMM2-CDG
- Timing of the initiation and completion of clinical trials
- Likelihood that data from clinical trials will support future development of product candidates
- Likelihood of obtaining regulatory approval of product candidates
Headwinds
- Plans to develop and commercialize product candidates
- The initiation, timing, progress and results of current and future preclinical studies and clinical trials and research and development programs
- Ability to take advantage of expedited regulatory pathways for any of product candidates
- Estimates regarding expenses, future revenue, capital requirements and needs for additional financing
- Ability to successfully acquire or license additional product candidates on reasonable terms
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports
-2.6%
Avg return
Earnings day
-9.9%
Avg return
5 days after
-14.9%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+24.0%
Q1 2025
Best reaction
-71.6%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -71.6% | -68.9% | -77.9% | |
| Q2 2025 | +5.6% | +9.1% | -5.6% | |
| Q1 2025 | +24.0% | -22.5% | -26.9% | |
| Q4 2024 | +0.1% | +4.3% | +1.5% | |
| Q3 2024 | +4.6% | +2.7% | -86.8% | |
| Q2 2024 | +5.7% | -4.4% | -6.4% | |
| Q1 2024 | -6.8% | -1.9% | -1.3% | |
| Q4 2023 | +7.3% | +2.6% | -6.2% | |
| Q3 2023 | -12.1% | -10.8% | +34.6% | |
| Q2 2023 | -3.2% | -14.1% | +1.3% | |
| Q1 2023 | -3.6% | -7.3% | -10.9% | |
| Q4 2022 | -5.6% | -7.9% | +6.3% | |
| Q3 2022 | -0.2% | — | — | |
| Q2 2022 | +3.0% | — | — | |
| Q1 2022 | -1.7% | — | — | |
| Q4 2021 | -9.1% | — | — | |
| Q3 2021 | +1.6% | — | — | |
| Q2 2021 | +3.6% | — | — | |
| Q1 2021 | -2.2% | — | — | |
| Q4 2020 | +3.3% | — | — | |
| Q3 2020 | +5.9% | — | — | |
| Q2 2020 | +13.8% | — | — | |
| Q1 2020 | +3.3% | — | — | |
| Q4 2019 | -27.7% | — | — | |
| Q3 2019 | -7.5% | — | — | |
| Q2 2019 | +7.0% | — | — | |
| Q1 2019 | -6.7% | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro